John Lansing's Trending123
John Lansing's Trending123
Username: Password: Login
Trade Talk E-Letter Products & Services Trading Tools Portfolios Members Home

Stock Sectors

(Click sector to view stock chart)

Drug Manufacturers Major

Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)


Schering-Plough Corporation engages in the discovery, development, manufacture, and marketing of medical therapies and treatments primarily in the United States, Canada, and Europe. The company also markets consumer brands in the over-the-counter (OTC), foot care, and sun care markets, as well as operates a global animal health business. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. The Prescription Pharmaceuticals segment manufactures and markets primary care products that include allergy/ respiratory, antibiotics, dermatologicals, and erectile dysfunction products, as well as specialty care products, such as anti-infectives, anti-inflammatories, oncology, acute coronary care, and other products for humans. It sells its products to hospitals, certain managed care organizations, wholesale distributors, and retail pharmacists. The Consumer Health Care segment manufactures and markets OTC, foot care, and sun care products. It sells its products through wholesale and retail drug, food chain, and mass merchandiser outlets. The Animal Health segment manufactures and markets animal health products to the livestock, poultry, companion animal, and aquaculture markets. It sells its products to veterinarians, distributors, and animal producers. Schering-Plough Corp. has a collaboration and license agreement with OncoMethylome Sciences for Schering-Plough to utilize assay technology from OncoMethylome Sciences that measures the methylation status of the MGMT gene in patients with glioblastoma multiforme, a form of malignant brain cancer, treated with temodar. The company was incorporated in 1970 and is headquartered in Kenilworth, New Jersey.


Aceto Corporation engages in the marketing, sale, and distribution of pharmaceutical, biopharmaceutical, specialty, and industrial chemicals used primarily in the agricultural, color producing, pharmaceutical, nutraceutical, and surface coating industries worldwide. It operates in three segments: Health Sciences, Chemicals and Colorants, and Agrochemicals. The Health Sciences segment includes the active ingredients for generic pharmaceuticals, vitamins, and nutritional supplements, as well as products used in preparing pharmaceuticals primarily by drug companies and biopharmaceuticals. The Chemicals and Colorants segment includes various specialty chemicals used in plastics, resins, adhesives, coatings, food, flavor additives, fragrances, cosmetics, metal finishing, electronics, air-conditioning systems, and other areas; dye and pigment intermediates used in the color-producing industries, such as textiles, inks, paper, and coatings; and intermediates used in the production of agrochemicals. The Agrochemicals segment offers herbicides, fungicides, and insecticides, as well as a sprout inhibitor for potatoes. Aceto Corporation was incorporated in 1947 and is headquartered in Lake Success, New York.


Merck & Co., Inc. engages in the discovery, development, manufacture, and marketing of a range of products to improve human and animal health. The company's products consist of therapeutic and preventive agents, sold by prescription, for the treatment and prevention of human disorders. It offers atherosclerosis products, which include Zocor; hypertension/heart failure products, including Cozaar, Hyzaar, and Vasotec; anti-inflammatory/analgesics, agents that specifically inhibit the COX-2 enzyme, which is responsible for pain and inflammation; an osteoporosis product, Fosamax, for treatment and prevention of osteoporosis; a respiratory product, Singulair, a leukotriene receptor antagonist for treatment of asthma and for relief of symptoms of seasonal allergic rhinitis; vaccines/biologicals, a live virus vaccine of chickenpox and hepatitis B vaccine; anti-bacterial/anti-fungal products, which include Primaxin, Cancidas, and Invanz; a urology product, Proscar, for treatment of symptomatic benign prostate enlargement; and HIV products, including Stocrin and Crixivan for the treatment of human immunodeficiency viral infection in adults. Its other products include Maxalt, for the treatment of acute migraine headaches in adults; and Propecia, for the treatment of male pattern hair loss. Merck & Co. has a collaboration agreement with Celera Diagnostics to develop treatments for Alzheimer's disease; and with Foxhollow Technologies, Inc. to focus on analyzing atherosclerotic plaque removed from patient arteries as a means of identifying biomarkers of atherosclerotic disease progression for use in the development of cardiovascular compounds. The company sells its products to drug wholesalers and retailers; hospitals; clinics; government agencies; and managed health care providers, such as health maintenance organizations and other institutions through its professional representatives. Merck & Co. was established in 1891 and is headquartered in Whitehouse Station, New Jersey.


Javelin Pharmaceuticals, Inc., together with its subsidiaries, engages in the research, development, and commercialization of products for pain relief in the United States. Its product candidates include Dyloject, which is in Phase III development stage for the treatment of post-operative pain in the United States, as well as in MAA Review stage for the treatment of acute forms of pain, including renal colic, exacerbations of osteo and rheumatoid arthritis, acute back pain, acute gout, acute trauma, and pain associated with fractures in Europe. The company's products also include Rylomine, an intranasal formulation of morphine that is in Phase III development stage for the treatment of acute moderate-to-severe pain and breakthrough pain in the United States and Europe; and PMI-150, a proprietary nasal formulation of ketamine that is under registration studies for the treatment of acute moderate-to-severe pain, including breakthrough pain in the United States. Its products also focus on treating various pain disorders, including episodic moderate-to-severe pain associated with breakthrough cancer pain; and post-trauma pain, such as orthopedic injury pain, procedural pain, and burn pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, license, manufacture, marketing, distribution, and sale of pharmaceutical and other health care products. The company primarily operates in three segments: Pharmaceuticals, Nutritionals, and Other Healthcare. The Pharmaceuticals segment provides branded pharmaceutical products for cardiovascular, virology, including human immunodeficiency virus, infectious diseases, oncology, affective disorders, and metabolics. It offers its products primarily to wholesalers, retail pharmacies, hospitals, government entities, and the medical professionals. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products, including a line of ENFAMIL products. The nutritional products are generally sold by wholesalers and retailers to healthcare professionals. The company's Other Healthcare segment consists of ConvaTec, Medical Imaging, and Consumer Medicines businesses. ConvaTec provides ostomy, and wound and skin care products. Medical Imaging offers cardiovascular imaging products, including radiopharmaceuticals and ultra-sound agents. Consumer Medicines provides consumer health care products for headache relief, analgesics, cold, cough, flu, and moisturizers, as well as for diabetics. BMS has strategic alliances with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; and Sankyo Company, Ltd. The company has a collaboration agreement with Ambit to discover kinase inhibitors; and with Domantis Limited to develop dAb therapeutics for uses in the fields of immunology and oncology. The company was founded in 1887. It was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers is headquartered in the New York City.


Abbott Laboratories engages in the discovery, development, manufacture, and sale of a line of health care products principally in the United States and Canada. The company operates through three segments: Pharmaceutical Products, Diagnostic Products, and Ross Products. The Pharmaceutical Products segment's products include a line of adult and pediatric pharmaceuticals, which are sold primarily on the prescription, or recommendation, of physicians. This segment sells its products directly to wholesalers, government agencies, health care facilities, and independent retailers in the United States through company-owned distribution centers and public warehouses. The Diagnostic Products segment's products consist of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and consumers. These products are sold directly to hospitals, laboratories, clinics, and physicians' offices. The Ross Products segment's products include a line of pediatric and adult nutritionals. This segment sells its products directly to physicians, health care facilities, and government agencies through wholesalers. Abbott Laboratories has a strategic alliance with Myriad Genetics, Inc. in pharmacogenetics that would focus on identifying human genetic variation around drug targets in various stages of development. The company was founded by Wallace Calvin Abbott in 1888. Abbott Laboratories is based in Abbott Park, Illinois.


Minrad International, Inc., together with its subsidiaries, operates as an interventional pain management company that focuses on anesthesia and analgesia, real-time image guidance, and conscious sedation areas. The company manufactures and markets generic inhalation anesthetics, including isoflurane, enflurane, sevoflurane, and desflurane for use in connection with human and veterinary surgical procedures. It also offers SabreSource real-time image guidance system and Light Sabre disposable products, which facilitate invasive surgery primarily for pain management, as well as has applications in orthopedics, neurosurgery, and interventional radiology. In addition, Minrad International develops a drug/drug delivery system for conscious sedation used in dental surgery that provides a patient with pain relief without loss of consciousness. Its products are sold through direct sales force and distribution partners to original equipment manufacturers primarily in North America, Europe, Asia, and Latin America. The company was founded in 1994 and is based in Orchard Park, New York.


Sanofi-Aventis engages in the research, development, manufacture, and marketing of pharmaceutical products for sale principally in the prescription market worldwide. The company offers prescription pharmaceuticals in six therapeutic areas: cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, and internal medicine. Its product portfolio includes Aprovel and Tritace, two hypertension treatment products for cardiovascular diseases; metabolic disorders products, which includes Lantus, a long acting analogue insulin and Amaryl, a once-daily sulfonylurea; oncology drugs that include Taxotere, a taxane derivative representing a cornerstone therapy in various cancer types, and Eloxatine, an platinum agent for metastatic colorectal cancer; central nervous system medicines, which include Stilnox for insomnia, Copaxone for multiple sclerosis, and Depakine for epilepsy treatments; and internal medicine products that include Allegra for respiratory/allergy, Nasacort for allergic rhinitis, Xatral for prostatic hypertrophy, and Actonel for osteoporosis. The company also offers various human vaccines, which include pediatric combination vaccines, influenza vaccines, polio vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel vaccines. As of December 31, 2004, Sanofi-Aventis had a total of 128 compounds in development in seven therapeutic areas, including 20 for vaccines, 48 of which were in phase II or phase III clinical trials. In addition, the company manufactures and markets various over the counter and generic products. It offers its products approximately in 100 countries. The company has alliances with Bristol-Myers Squibb, Procter & Gamble Pharmaceuticals, Genfit, Millennium, Cerep, GeneLogic, Astex, Amphora, Immunogen, Coley, Mitsubishi Pharmaceutical Corp, Cephalon, Regeneron Pharmaceuticals, Immuno-Design Molecule, ALTANA AG, YM BioSciences, Inc., and Pfizer, Inc. Sanofi-Aventis is headquartered in Paris, France.


Eli Lilly and Company engages in the discovery, development, manufacture, and sale of primarily pharmaceutical products in the United States and internationally. The company's products include neuroscience products, which include Zyprexa, Prozac, Strattera, Cymbalta, Permax, Symbyax, and Yentreve; endocrinology products that consist primarily of Humalog, Humulin, Actos, Evista, Forteo, and Humatrope; and oncology products, which comprise primarily of Gemzar and Alimta. It also offers cardiovascular products that consist primarily of ReoPro and Xigris; and anti-infectives, which primarily include Ceclor and Vancocin. The other pharmaceutical product group includes Cialis, Axid, and other miscellaneous pharmaceutical products and services. In addition, Eli Lilly offers animal health products that include Tylan, Rumensin, Coban, and other products for livestock and poultry. It primarily sells its pharmaceutical products through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Eli Lilly has a collaboration agreement with HistoRx, Inc. to apply the HistoRx AQUA platform for quantitative pathology analysis; and with Alkermes, Inc. to develop and commercialize inhaled formulations of parathyroid hormone for the treatment of osteoporosis. The company was founded by Eli Lilly in 1876 and is based in Indianapolis, Indiana.


Johnson & Johnson engages in the manufacture and sale of various products in the health care field primarily in the United States. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics (MDD). Consumer segment manufactures and markets a range of products used in the baby and child care, skin care, oral and wound care, and women's health care fields, as well as over-the-counter pharmaceutical and nutritional products. These products are marketed primarily to the general public; and sold to wholesalers, and directly to independent and chain retail outlets worldwide. Pharmaceutical segment franchises various products in the anti-fungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic, and urology fields. These products are distributed directly, and through wholesalers and health care professionals for use by prescription by the general public. MDD segment offers a range of products, including wound care and women's health products; minimally invasive surgical products; circulatory disease management products; blood glucose monitoring products; professional diagnostic products; orthopedic joint reconstruction, spinal, and sports medicine products; and disposable contact lenses. These products are distributed directly and through surgical suppliers and other dealers for use by or under the direction of physicians, nurses, therapists, hospitals, diagnostic laboratories, and clinics. Johnson & Johnson has an agreement with Bayer AG to jointly develop and market a compound labelled BAY 59-7939 for the prevention and treatment of thrombosis. The company was founded by Robert Wood Johnson in 1887. Johnson & Johnson is headquartered in New Brunswick, New Jersey.


GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products worldwide. The company operates in two segments, Pharmaceuticals and Consumer Healthcare. The Pharmaceutical segment offers prescription pharmaceuticals and vaccines. Its primary pharmaceutical products include medicines in nine therapeutic areas, including central nervous system, respiratory, anti-virals, anti-bacterials, vaccines, oncology and emesis, metabolic, cardiovascular, and urogenital. The Consumer Healthcare segment provides various over-the-counter medicines, oral care, and nutritional healthcare products. Its oral care products include toothpastes and mouthwashes, toothbrushes, and denture care products. Its nutritional healthcare products include glucose energy and sports drinks, a blackcurrant juice-based drink with vitamin C, and a range of milk-based malted food and chocolate drinks. GlaxoSmithKline has a strategic alliance with Theravance, Inc. to develop and commercialise medicines across a various therapeutic areas; Cytokinetics, Inc. to discover, develop, and commercialize small molecule drugs targeting kinesin spindle protein and certain other cytoskeletal proteins involved in cell proliferation for applications in the treatment of cancer and other diseases; and a partnership with Aeras Global TB Vaccine Foundation to develop GSK Biologicals' tuberculosis candidate vaccine Mtb72F/AS02A. The company was founded in 1935 and is headquartered in London.


Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals, as well as consumer healthcare products worldwide. It operates in three segments: Human Health, Consumer Healthcare, and Animal Health. The Human Health segment offers treatments for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders, and allergies. The Consumer Healthcare segment markets over-the-counter medications for oral care, upper respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care, and hair growth. Its principal products include Listerine mouthwash, Listerine PocketPaks oral care strips, Nicorette for tobacco dependence, Benadryl antihistamine for allergies, Sudafed for sinus congestion, Rogaine for hair growth, Zantac 75 for prevention and relief of heartburn, Rolaids antacid tablets, Efferdent denture cleaner, Neosporin antibiotic ointment, Visine eye drops, BenGay topical analgesic, Cortizone skin care products, Lubriderm moisturizing lotions, Unisom sleep aids, Desitin ointments for treatment of diaper rash, Ludens throat drops, and Purell instant hand sanitizer. The Animal Health segment offers products for the prevention and treatment of diseases in livestock and animals. Its products include parasiticides, anti-inflammatories, vaccines, antibiotics, and related medicines. In addition, the company offers empty soft-gelatin capsules, contract manufacturing, and bulk pharmaceutical chemicals. Pfizer has an agreement with Power 3 Medical Products, Inc. to evaluate the NuroPro test capabilities and to test blind and unblinded samples provided by Pfizer; and a research and license agreement with Incyte Corp. for the development, manufacture, and marketing of oral CCR2 antagonists. The company was founded in 1849 and is headquartered in New York City.


Novartis AG engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in three divisions: Pharmaceuticals, Consumer Health, and Sandoz. Pharmaceuticals division develops, markets, and sells branded pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism, neuroscience, respiratory and dermatology, specialty medicines, oncology and hematology, transplantation and immunology, and ophthalmic diseases, as well as arthritis, bone, gastrointestinal, hormone replacement therapy, and infectious diseases. Consumer Health division operates five units, such as over-the-counter self-medication products, animal health, medical nutrition, infant and baby foods, and lens and vision care. Sandoz division develops, manufactures, markets, and sells retail generics drugs, and off-patent active pharmaceutical ingredients and intermediates to wholesalers, pharmacies, hospitals, and other healthcare outlets. It also provides biopharmaceutical products, such as protein hormones and other human proteins. Novartis has a collaboration agreement with Alnylam Pharmaceuticals, Inc. focused on the discovery of therapeutics based on RNA interference; with Avalon to discover and develop small molecule therapeutics for an undisclosed indication; with Vernalis plc focused on the oncology target Hsp90; with Ablynx nv to discover and develop therapeutic Nanobodies; and with Ono Pharmaceutical Co., Ltd. to develop and market rivastigmine transdermal patch in Japan for the treatment of Alzheimer's disease. The company sells its products to physicians, pharmacists, hospitals, insurance groups, and managed care organizations. Novartis was formed in 1895 and is headquartered in Basel, Switzerland.


Abraxis BioScience, Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of injectable products for the treatment of cancer and other life-threatening diseases. It markets approximately 150 injectable products in approximately 400 dosage forms in the areas of oncology, anti-infectives, and critical care. The company's proprietary injectable oncology product is ABRAXANE, for the treatment of metastatic breast cancer. Its other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of solid tumors; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of solid tumors; and Coroxane for the treatment of coronary artery restenosisis. Abraxis BioScience markets its products through its direct sales force to hospitals, long-term care facilities, alternate care sites, clinics, and doctors in North America. The company has strategic relationships with AstraZeneca UK Limited and Taiho Pharmaceutical Co., Ltd., as well as a joint venture agreement with Cenomed, Inc. to research and develop drugs focusing on psychiatric and neurological diseases. Abraxis BioScience was founded in 1996 and is based in Los Angeles, California.


Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule product candidates for the treatment of unmet medical needs. It has three product development programs, such as allergy/asthma, rheumatoid arthritis, and cancer. The company develops R112, which is in Phase II clinical trial for the treatment of allergic rhinitis; and R406/788 that is in Phase I clinical study for the treatment of rheumatoid arthritis. Rigel's another product candidate R406 is in preclinical studies, which is an oral Syk kinase inhibitor that blocked the activation of mast cells and B cells that promote the swelling and inflammatory response. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; and Merck and Co., Inc. Rigel was incorporated in 1996 and is based in South San Francisco, California.


Wyeth engages in the discovery, development, manufacture, distribution, and sale of pharmaceuticals, vaccines, biotechnology products, nonprescription medicines, and animal health care products worldwide. It operates in three segments: Pharmaceuticals, Consumer Healthcare, and Animal Health. The Pharmaceuticals segment manufactures and distributes branded human ethical pharmaceuticals, biologicals, vaccines, and nutritionals. Its principal products include neuroscience therapies, cardiovascular products, nutritionals, gastroenterology drugs, anti-infectives, vaccines, oncology therapies, musculoskeletal therapies, hemophilia treatments, immunological products, and women's health care products. The Consumer Healthcare segment sells over-the-counter health care products, which include analgesics, cough/cold/allergy remedies, and nutritional supplements, as well as hemorrhoidal, asthma, and other relief items. The Animal Health segment offers animal biological and pharmaceutical products that comprise vaccines, pharmaceuticals, parasite control, and growth implants. The company sells its products to wholesalers, pharmacies, hospitals, physicians, retailers, health care institutions, and veterinarians located in various markets in approximately 140 countries. Wyeth has discovery research collaboration with Neurome, Inc. focused on the investigation of certain aspects of central nervous system disease using Neurome's proprietary discovery technologies in quantitative neuropathology. The company was incorporated in 1926 as American Home Products Corporation and changed its name to Wyeth in 2002. Wyeth is headquartered in Madison, New Jersey.


AstraZeneca PLC, a pharmaceutical company, engages in the research, development, manufacture, and marketing of prescription pharmaceuticals, as well as the supply of healthcare services worldwide. It provides medicines designed to fight disease in areas of medical need, such as cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory. The company's product portfolio includes Casodex, Arimidex, and Faslodex for treating cancer; disease Nexium for gastrointestinal problems; Symbicort for asthma; Atacand for treating hypertension; Crestor for treating high cholesterol; Zomig for treating migraine; and Seroquel for treating schizophrenia. AstraZeneca has strategic alliance with Cambridge Antibody Technology (CAT) for discovering and developing human antibody therapeutics in inflammatory disorders. In addition, it also engages in research and development, manufacture, and marketing of medical devices and implants for use in healthcare. AstraZeneca has a collaboration agreement with Caprion Pharmaceuticals, Inc. focused on the discovery of targets for the treatment of prostate cancer; with Avanir Pharmaceuticals to evaluate the human safety of AZD2479, a compound under development as reverse cholesterol transport enhancer; with University of Texas MD Anderson Cancer Center for integrated preclinical and clinical research on new treatments for cancer, focusing initially on aerodigestive diseases; and with Targacept, Inc. to develop and commercialize Targacept's phase II compound TC-1734 to treat Alzheimer's disease and schizophrenia. The company was incorporated in 1992 and was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999. AstraZeneca PLC is headquartered in London.


Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of prescription drug products for the treatment of cancer and related disorders. The company has six drug candidates in clinical development, including Satraplatin for hormone refractory prostate cancer and nonsmall cell lung cancer; EOquin for refractory superficial bladder cancer; Elsamitrucin for refractory nonhodgkin's lymphoma; SPI-153 for hormone dependent prostate cancer and benign prostatic hypertrophy; EO9 for radiation sensitization; RenaZorb for end-stage renal disease and chronic kidney disease; and SPI-1620 for adjunct to chemotherapy. Its Satraplatin product is in phase III clinical trial; EOquin, Elsamitrucin, and SPI-153 products are in phase II clinical trials; and EO9, RenaZorb, and SPI-1620 products are in preclinical trials. The company has strategic alliances with GPC Biotech AG, Johnson Matthey PLC, Bristol-Myers Squibb, Zentaris GmbH, Altair Nanotechnologies, Inc., Chicago Labs, J.B. Chemicals & Pharmaceuticals, Ltd., FDC Limited, and Shantha Biotechnics Pvt., Ltd. The company was incorporated as Americus Funding Corporation in 1987 and changed its name to NeoTherapeutics, Inc. in 1996. NeoTherapeutics changed its name to Spectrum Pharmaceuticals, Inc. in 2002. The company is headquartered in Irvine, California.


Keryx Biopharmaceuticals, Inc., a development stage company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company has two product candidates in the later stages of clinical development, which include sulodexide, or KRX-101, for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes; and perifosine or KRX-0401 for the treatment of multiple forms of cancer. Its other drug portfolio includes three clinical stage oncology compounds, designated as KRX-0402 and KRX-0403. The company has strategic alliances with Alfa Wassermann S.p.A.; Zentaris AG; Opocrin, S.p.A.; Paligent, Inc.; Collaborative Study Group; and Prescient NeuroPharma, Inc. The company was incorporated in 1998 under the name Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999 and to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is headquartered in New York City.


Interpharm Holdings, Inc. engages in the development, manufacture, and marketing of generic prescription strength and over-the-counter pharmaceutical products. It primarily manufactures 23 generic drug products, which represent various oral dosage strengths for 13 distinct products, as well as 14 generic products of various dosage strengths of 4 distinct products. The company's product pipeline focuses in six areas, including female hormone products, scheduled narcotics, products requiring special release characteristics, liquid products, softgel products, and products coming off patent. It markets its products to wholesalers, distributors, and repackagers primarily in the United States. Interpharm Holdings has strategic alliances with Tris Pharma, Inc. and Centrix Pharmaceutical, Inc. The company is based in Hauppauge, New York.


GeoPharma, Inc. engages in the manufacture, package, and distribution of various health-related products for companies worldwide. The company develops and manufactures a range of nutritional supplements; dietary supplements, and health and beauty care products for distribution through various outlets; over-the-counter drugs and repackages generic drugs; and foods for the low-carbohydrate lifestyle. Its pharmacy benefit management subsidiary, Go2PBM Services, Inc, manages multiple health care plan members and the administration of their related pharmacy claims. The company was incorporated in 1985 as Energy Factors, Inc. and changed its name to Innovative Health Products, Inc. in 1998. It further changed its name to, Inc. in February 2000; to Go2Pharmacy, Inc. in September 2000; to Innovative Companies, Inc. in 2002; and to GeoPharma, Inc. in 2004. GeoPharma is based in Largo, Florida.


Novogen Limited, a pharmaceutical company, engages in the discovery, development, manufacture, and marketing of products based on the isoflavoniod technology. Its product development program comprises a novel range of pharmaceuticals based on phenolic compounds in humans, and dietary supplements based on plant compounds known as isoflavones. The company's products include Promensil, which provides natural relief from the symptoms of menopause, such as hot flushes and night sweats; Trinovin, which maintains normal prostate and urinary function, health and quality of life in men; and Rimostil that maintains bone and cholesterol health, and also to promote health and well-being in women after menopause. In addition, Novogen develops phenoxodiol, which is in phase II clinical trials for the treatment of prostate cancer, ovarian cancer, renal cancer, and squamous cell carcinomas of the cervix, vagina, and vulva. It is also developing NV-04, a cardiovascular drug candidate; and NV-07, an anti-inflammatory drug candidate. The company sells its products through its distributors and other third parties in Australia, New Zealand, the United States, Canada, and certain European countries. Novogen was founded by Graham E. Kelly in 1994. It was formerly known as Norvet Limited. The company is headquartered in North Ryde, Australia.


A.P. Pharma, Inc., a specialty pharmaceutical company, develops pharmaceutical products utilizing its polymer-based drug delivery systems. The company offers Retin-A Micro, a dermatological product based on Microsponge technology; and Carac, a chemotherapeutic product. It focuses on the development and commercialization of bioerodible injectable and implantable systems under the name of Biochronomer. In addition, A.P. Pharma develops APF530 product for the prevention of acute and delayed chemotherapy-induced nausea and vomiting; and APF112 product for the treatment of post-surgical pain. Its APF530 completed a phase I trial and APF112 completed Phase II human clinical trials. The company was founded as AMCO Polymerics, Inc. in 1983 and changed its name to Advanced Polymer Systems, Inc. in 1984. Further, Advanced Polymer Systems changed its name to A.P. Pharma, Inc. in 2001. A.P. Pharma is based in Redwood City, California.


Oscient Pharmaceuticals Corporation engages in the clinical development and commercialization of therapeutics. Its lead product candidate, fluoroquinolone antibiotic FACTIVE tablet, is indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. The company is developing an antibiotic candidate, Ramoplanin, which is in a phase II trial for the treatment of Clostridium difficile-associated diarrhea. In addition, Oscient has various preclinical development programs, including an oral peptide deformylase inhibitor series for the potential treatment of respiratory tract infections, as well as the development of a FACTIVE intravenous formulation. The company has alliances with AstraZeneca PLC; Schering-Plough, Ltd.; bioMerieux Incorporated; Amgen, Inc.; and Wyeth for the discovery and development of therapeutics for chronic human diseases and certain infectious diseases. The company was founded by Orrie M. Friedman in 1961 under the name Collaborative Research, Inc. It changed its name to Genome Therapeutics Corporation in 1994 and to Oscient Pharmaceuticals Corporation in 2004. Oscient Pharmaceuticals is headquartered in Waltham, Massachusetts.